Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement

INTRODUCTION: While adalimumab is licensed for ankylosing spondylitis (AS), open uncontrolled studies suggest therapeutic efficacy of TNF-inhibitors in juvenile onset AS (JoAS). METHODS: A total of 32 patients aged 12 to 17 years with severe, active and refractory JoAS were enrolled in a multicenter...

Descripción completa

Detalles Bibliográficos
Autores principales: Horneff, Gerd, Fitter, Sigrid, Foeldvari, Ivan, Minden, Kirsten, Kuemmerle-Deschner, Jasmin, Tzaribacev, Nicolay, Thon, Angelika, Borte, Michael, Ganser, Gerd, Trauzeddel, Rolf, Huppertz, Hans-Iko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3580542/
https://www.ncbi.nlm.nih.gov/pubmed/23095307
http://dx.doi.org/10.1186/ar4072

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3580542/
https://www.ncbi.nlm.nih.gov/pubmed/23095307
http://dx.doi.org/10.1186/ar4072

Ejemplares similares